{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:34:38Z","timestamp":1777386878144,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00125-009-1530-5","type":"journal-article","created":{"date-parts":[[2009,9,14]],"date-time":"2009-09-14T15:16:26Z","timestamp":1252941386000},"page":"2499-2506","source":"Crossref","is-referenced-by-count":116,"title":["Combined randomised controlled trial experience of malignancies in studies using insulin glargine"],"prefix":"10.1007","volume":"52","author":[{"given":"P. D.","family":"Home","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lagarenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,15]]},"reference":[{"key":"1530_CR1","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00125-009-1453-1","volume":"52","author":"HM Colhoun","year":"2009","unstructured":"Colhoun HM, on behalf of the SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755\u20131765","journal-title":"Diabetologia"},{"key":"1530_CR2","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","volume":"52","author":"CJ Currie","year":"2009","unstructured":"Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766\u20131777","journal-title":"Diabetologia"},{"key":"1530_CR3","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00125-009-1418-4","volume":"52","author":"LG Hemkens","year":"2009","unstructured":"Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732\u20131744","journal-title":"Diabetologia"},{"key":"1530_CR4","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00125-009-1444-2","volume":"52","author":"JM Jonasson","year":"2009","unstructured":"Jonasson JM, Ljung R, Talb\u00e4ck M, Haglund B, Gudbj\u00f6rnsd\u00f2ttir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies\u2014a population-based follow-up study in Sweden. Diabetologia 52:1745\u20131754","journal-title":"Diabetologia"},{"key":"1530_CR5","unstructured":"Northrup Grumman (2009) Medical dictionary for regulatory activities. Available at www.meddramsso.com\/MSSOWeb\/index.htm , accessed 10 August 2009"},{"key":"1530_CR6","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2009) ICH Guidelines. Available at www.ich.org\/UrlGrpServer.jser?@_ID=276&@_TEMPLATE=254 , accessed 10 August 2009"},{"key":"1530_CR7","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00125-009-1415-7","volume":"52","author":"J Rosenstock","year":"2009","unstructured":"Rosenstock J, Fonseca V, McGill JB et al (2009) Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 52:1778\u20131788","journal-title":"Diabetologia"},{"key":"1530_CR8","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00125-009-1452-2","volume":"52","author":"J Rosenstock","year":"2009","unstructured":"Rosenstock J, Fonseca V, McGill JB et al (2009) Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5\u00a0year randomised, open-label study. Diabetologia 52:1971\u20131973","journal-title":"Diabetologia"},{"key":"1530_CR9","unstructured":"Huang XF, Chen JZ (2009) Obesity, the PI3K\/Akt signal pathway and colon cancer. Obes Rev. doi: 10.1111\/j.1467-1789X.2009.00607.x"},{"key":"1530_CR10","unstructured":"Cancer Research UK (2009) UK cancer incidence statistics by age. Available at http:\/\/info.cancerresearchuk.org\/cancerstats\/incidence\/age\/?a=5441 , accessed 10 August 2009"},{"key":"1530_CR11","unstructured":"World Health Organisation (International Agency for Research on Cancer) (2009) CANCERMondial. Available at www-dep.iarc.fr\/ , accessed 10 August 2009"},{"key":"1530_CR12","unstructured":"European Medicines Agency (2002) ICH Topic E 6 (R1)\u2014Guideline for good clinical practice. Available at www.emea.europa.eu\/pdfs\/human\/ich\/013595en.pdf , accessed 10 August 2009"},{"key":"1530_CR13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","volume":"32","author":"J Dormandy","year":"2009","unstructured":"Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR (2009) Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 32:187\u2013202","journal-title":"Drug Saf"},{"key":"1530_CR14","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125\u20132135","journal-title":"Lancet"},{"key":"1530_CR15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/diacare.23.8.1137","volume":"23","author":"J Rosenstock","year":"2000","unstructured":"Rosenstock J, Park G, Zimmerman J (2000) Basal insulin glargine (HOE 901) vs NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 23:1137\u20131142","journal-title":"Diabetes Care"},{"key":"1530_CR16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/diacare.23.2.157","volume":"23","author":"TR Pieber","year":"2000","unstructured":"Pieber TR, Eugene-Jolchine I, Derobert E (2000) Efficacy and safety of HOE 901 vs NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 23:157\u2013162","journal-title":"Diabetes Care"},{"key":"1530_CR17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/dmrr.572","volume":"21","author":"PD Home","year":"2005","unstructured":"Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A (2005) A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 21:545\u2013553","journal-title":"Diabetes Metab Res Rev"},{"key":"1530_CR18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1515\/JPEM.2002.15.4.369","volume":"15","author":"E Schober","year":"2002","unstructured":"Schober E, Schoenle E, van Dyk J, Wernicke-Panten K (2002) Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 15:369\u2013376","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1530_CR19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2337\/diacare.23.5.639","volume":"23","author":"RE Ratner","year":"2000","unstructured":"Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA (2000) Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23:639\u2013643","journal-title":"Diabetes Care"},{"key":"1530_CR20","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.2337\/diacare.23.11.1666","volume":"23","author":"P Raskin","year":"2000","unstructured":"Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T (2000) A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23:1666\u20131671","journal-title":"Diabetes Care"},{"key":"1530_CR21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2337\/diacare.26.3.799","volume":"26","author":"NP Murphy","year":"2003","unstructured":"Murphy NP, Keane SM, Ong KK et al (2003) Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 26:799\u2013804","journal-title":"Diabetes Care"},{"key":"1530_CR22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1464-5491.2005.01781.x","volume":"23","author":"SG Ashwell","year":"2006","unstructured":"Ashwell SG, Amiel SA, Bilous RW et al (2006) Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 23:285\u2013292","journal-title":"Diabet Med"},{"key":"1530_CR23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1445-5994.2005.00902.x","volume":"35","author":"GR Fulcher","year":"2005","unstructured":"Fulcher GR, Gilbert RE, Yue DK (2005) Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 35:536\u2013542","journal-title":"Intern Med J"},{"key":"1530_CR24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jpeds.2008.04.063","volume":"153","author":"HP Chase","year":"2008","unstructured":"Chase HP, Arslanian S, White NH, Tamborlane WV (2008) Insulin glargine vs intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus. J Pediatr 153:547\u2013553","journal-title":"J Pediatr"},{"key":"1530_CR25","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc08-1874","volume":"32","author":"GB Bolli","year":"2009","unstructured":"Bolli GB, Kerr D, Thomas R et al (2009) Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 32:1170\u20131176","journal-title":"Diabetes Care"},{"key":"1530_CR26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1464-5491.2003.00999.x","volume":"20","author":"HOE 901\/2004 Study Investigators Group","year":"2003","unstructured":"HOE 901\/2004 Study Investigators Group (2003) Safety and efficacy of insulin glargine (HOE 901) vs NPH insulin in combination with oral treatment in type 2 diabetic patients. Diabet Med 20:545\u2013551","journal-title":"Diabet Med"},{"key":"1530_CR27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-2003-39080","volume":"35","author":"M Massi Benedetti","year":"2003","unstructured":"Massi Benedetti M, Humburg E, Dressler A, Ziemen M (2003) A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 35:189\u2013196","journal-title":"Horm Metab Res"},{"key":"1530_CR28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/diacare.24.4.631","volume":"24","author":"J Rosenstock","year":"2001","unstructured":"Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631\u2013636","journal-title":"Diabetes Care"},{"key":"1530_CR29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1464-5491.2006.01881.x","volume":"23","author":"HC Gerstein","year":"2006","unstructured":"Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E (2006) A randomized trial of adding insulin glargine vs avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and\/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med 23:736\u2013742","journal-title":"Diabet Med"},{"key":"1530_CR30","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","volume":"138","author":"A Fritsche","year":"2003","unstructured":"Fritsche A, Schweitzer MA, Haring HU (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138:952\u2013959","journal-title":"Ann Intern Med"},{"key":"1530_CR31","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","volume":"26","author":"MC Riddle","year":"2003","unstructured":"Riddle MC, Rosenstock J, Gerich J (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care 26:3080\u20133086","journal-title":"Diabetes Care"},{"key":"1530_CR32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.diabres.2006.08.012","volume":"76","author":"CY Pan","year":"2007","unstructured":"Pan CY, Sinnassamy P, Chung KD, Kim KW (2007) Insulin glargine vs NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Res Clin Pract 76:111\u2013118","journal-title":"Diabetes Res Clin Pract"},{"key":"1530_CR33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.arcmed.2005.10.015","volume":"37","author":"FG Eliaschewitz","year":"2006","unstructured":"Eliaschewitz FG, Calvo C, Valbuena H et al (2006) Therapy in type 2 diabetes: insulin glargine vs NPH insulin both in combination with glimepiride. Arch Med Res 37:495\u2013501","journal-title":"Arch Med Res"},{"key":"1530_CR34","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/diacare.29.03.06.dc05-0695","volume":"29","author":"J Rosenstock","year":"2006","unstructured":"Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G (2006) Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29:554\u2013559","journal-title":"Diabetes Care"},{"key":"1530_CR35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.28.2.254","volume":"28","author":"HU Janka","year":"2005","unstructured":"Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-J\u00e4rvinen H (2005) Comparison of basal insulin added to oral agents vs twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28:254\u2013259","journal-title":"Diabetes Care"},{"key":"1530_CR36","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0140-6736(08)60485-7","volume":"371","author":"RG Bretzel","year":"2008","unstructured":"Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T (2008) Once-daily basal insulin glargine vs thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371:1073\u20131084","journal-title":"Lancet"},{"key":"1530_CR37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1463-1326.2008.00980.x","volume":"11","author":"JF Blickle","year":"2009","unstructured":"Blickle JF, Hancu N, Piletic M et al (2009) Insulin glargine provides greater improvements in glycaemic control vs intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7\u20138% A1c levels. The TULIP study. Diabetes Obes Metab 11:379\u2013386","journal-title":"Diabetes Obes Metab"},{"key":"1530_CR38","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","volume":"49","author":"H Yki-J\u00e4rvinen","year":"2006","unstructured":"Yki-J\u00e4rvinen H, Kauppinen-Makelin R, Tiikkainen M et al (2006) Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49:442\u2013451","journal-title":"Diabetologia"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-009-1530-5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,7]],"date-time":"2019-04-07T01:44:33Z","timestamp":1554601473000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-009-1530-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,15]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1530"],"URL":"https:\/\/doi.org\/10.1007\/s00125-009-1530-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1427961.904061","asserted-by":"object"}]},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,15]]}}}